Breast Cancer: Targets and Therapy
Volume 14, 2022 - Issue
Open access
166
Views
0
CrossRef citations to date
0
Altmetric
REVIEW
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
Yongchao Yu1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China;2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People’s Republic of China;3 Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
https://orcid.org/0000-0002-2388-8730
Jin Wang1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China;2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People’s Republic of China;3 Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
, Dongying Liao1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China;2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People’s Republic of China;3 Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
, Dou Zhang1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China;2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People’s Republic of China;3 Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
, Xiaojiang Li1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China;2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People’s Republic of China
, Yingjie Jia1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China;2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People’s Republic of China
& Fanming Kong1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China;2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People’s Republic of China;3 Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of ChinaCorrespondence[email protected]
show all
Pages 417-432
|
Received 05 Aug 2022, Accepted 17 Nov 2022, Published online: 04 Dec 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.